MarkTRedingMD
Oncology • Minneapolis, MNAssistant Professor, Medicine, University of Minnesota Medical School
Telehealth Available
Overview of Dr. Reding
Dr. Mark Reding is an oncologist in Minneapolis, MN and is affiliated with multiple hospitals in the area, including M Health Fairview University of Minnesota Medical Center, M Health Fairview Southdale Hospital, and M Health Fairview Ridges Hospital. He received his medical degree from University of Minnesota Medical School and has been in practice 25 years. He is one of 88 doctors at M Health Fairview University of Minnesota Medical Center and one of 30 doctors at M Health Fairview Ridges Hospital who specialize in Oncology. He has more than 50 publications and over 500 citings.
Office
420 Delaware St Se
Mmc 480
Minneapolis, MN 55455
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 1996 - 1999- University of MinnesotaResidency, Internal Medicine, 1992 - 1995
- University of Minnesota Medical SchoolClass of 1992
Certifications & Licensure
MN State Medical License 1994 - 2025
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Inhibitor Development in Patients With Hemophilia A Undergoing Surgery Start of enrollment: 2011 Nov 01
- Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B Start of enrollment: 2013 Feb 11
- Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis Start of enrollment: 2014 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.Mark T Reding, Mindy Simpson, Jonathan Ducore, Pål Andrè Holme, Monika Maas Enriquez
Acta Haematologica. 2024-04-23 - Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with he...Mark T Reding, María Teresa Álvarez-Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita
European Journal of Haematology. 2024-02-01 - 10 citationsBuilding the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people wit...Duc Q Tran, Craig C Benson, Judith A Boice, Meera Chitlur, Amy L Dunn
Expert Review of Hematology. 2023-03-01
Press Mentions
Bayer to Present Results from Head-to-Head PK Comparison Study of Jivi® Versus Adynovate® in Late-Breaker Presentation at the Annual World Federation of Hemophilia Virtual SummitJune 15th, 2020
FDA Approves JiviAugust 31st, 2018
